Dual Anticancer and Antimicrobial Activity of A Novel Dual-Drug Nanosystem for Co-Delivery of Curcumin and Cyclotides Derived from Viola Dalatensis Gagnep

IF 3.6 4区化学 Q2 CHEMISTRY, INORGANIC & NUCLEAR

Journal of Cluster Science Pub Date : 2025-08-19 DOI:10.1007/s10876-025-02892-1

Trung Dinh Nguyen, Tam T.T. Tran, Son H. Pham, Tien T. Dang

{"title":"Dual Anticancer and Antimicrobial Activity of A Novel Dual-Drug Nanosystem for Co-Delivery of Curcumin and Cyclotides Derived from Viola Dalatensis Gagnep","authors":"Trung Dinh Nguyen, Tam T.T. Tran, Son H. Pham, Tien T. Dang","doi":"10.1007/s10876-025-02892-1","DOIUrl":null,"url":null,"abstract":"<div><p>The article presents a robust technique for nanoparticle manufacturing that employs hydrophobic and electrostatic interactions, utilizing curcumin (Cur) and cyclotides (Cyc) as pharmacological models. The CS/HA/P407@Cyc@Cur nanosystem, confirmed using FTIR, UV-Vis, and DLS, exhibited consistent physicochemical characteristics: diameter (182.6 ± 10.7 nm), PDI (0.381 ± 0.07), and zeta potential (-30 mV), hence ensuring colloidal stability. High loading efficiency (LE: 90.42–93.09%) and encapsulation capacity (LC: 4.17–4.73%) validated the effective co-loading of Cur and Cyc. The nanosystem demonstrated pH-responsive drug release in acidic tumor microenvironments and remarkable stability, maintaining 82.87% Cur in DMEM. Antibacterial experiments demonstrated significant action against gram-positive bacteria and moderate effectiveness against gram-negative pathogens. Hemocompatibility was exceptional, with hemolysis below 2% across all concentrations. Both free and nanoparticle-encapsulated @Cyc@Cur significantly inhibited MCF-7 breast cancer cell proliferation at low doses, underscoring their therapeutic potential. The technology’s adaptability facilitates future integration for synergistic dual-drug delivery, especially with antibiotics and anticancer drugs, presenting exciting opportunities for the treatment of infections, cancers, and hematological disorders through intravenous injection.</p><h3>Graphical Abstract</h3><div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":618,"journal":{"name":"Journal of Cluster Science","volume":"36 5","pages":""},"PeriodicalIF":3.6000,"publicationDate":"2025-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cluster Science","FirstCategoryId":"92","ListUrlMain":"https://link.springer.com/article/10.1007/s10876-025-02892-1","RegionNum":4,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, INORGANIC & NUCLEAR","Score":null,"Total":0}

引用次数: 0

Abstract

The article presents a robust technique for nanoparticle manufacturing that employs hydrophobic and electrostatic interactions, utilizing curcumin (Cur) and cyclotides (Cyc) as pharmacological models. The CS/HA/P407@Cyc@Cur nanosystem, confirmed using FTIR, UV-Vis, and DLS, exhibited consistent physicochemical characteristics: diameter (182.6 ± 10.7 nm), PDI (0.381 ± 0.07), and zeta potential (-30 mV), hence ensuring colloidal stability. High loading efficiency (LE: 90.42–93.09%) and encapsulation capacity (LC: 4.17–4.73%) validated the effective co-loading of Cur and Cyc. The nanosystem demonstrated pH-responsive drug release in acidic tumor microenvironments and remarkable stability, maintaining 82.87% Cur in DMEM. Antibacterial experiments demonstrated significant action against gram-positive bacteria and moderate effectiveness against gram-negative pathogens. Hemocompatibility was exceptional, with hemolysis below 2% across all concentrations. Both free and nanoparticle-encapsulated @Cyc@Cur significantly inhibited MCF-7 breast cancer cell proliferation at low doses, underscoring their therapeutic potential. The technology’s adaptability facilitates future integration for synergistic dual-drug delivery, especially with antibiotics and anticancer drugs, presenting exciting opportunities for the treatment of infections, cancers, and hematological disorders through intravenous injection.

Graphical Abstract

Abstract Image

查看原文本刊更多论文

一种新型双药纳米系统共递送紫堇姜黄素和环肽的抗癌和抗菌活性

本文提出了一种强大的纳米颗粒制造技术，利用疏水和静电相互作用，利用姜黄素（Cur）和环聚糖（Cyc）作为药理学模型。CS/HA/P407@Cyc@Cur纳米体系经FTIR、UV-Vis和DLS验证，具有一致的物理化学特性：直径（182.6±10.7 nm）、PDI（0.381±0.07）和zeta电位（-30 mV），从而保证了胶体稳定性。高负载效率（LE: 90.42 ~ 93.09%）和包封量（LC: 4.17 ~ 4.73%）验证了Cur和Cyc的有效共负载。该纳米系统在酸性肿瘤微环境中表现出ph响应性药物释放和显著的稳定性，在DMEM中保持82.87%的Cur。抗菌实验表明，对革兰氏阳性菌有显著的抑菌作用，对革兰氏阴性菌的抑菌效果中等。血液相容性异常，所有浓度的溶血率均低于2%。游离和纳米颗粒封装@Cyc@Cur在低剂量下显著抑制MCF-7乳腺癌细胞增殖，强调其治疗潜力。该技术的适应性促进了未来双药协同递送的整合，特别是与抗生素和抗癌药物的整合，为通过静脉注射治疗感染、癌症和血液系统疾病提供了令人兴奋的机会。图形抽象

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Cluster Science 化学-无机化学与核化学

CiteScore

6.70

自引率

0.00%

发文量

166

审稿时长

3 months

期刊介绍： The journal publishes the following types of papers: (a) original and important research; (b) authoritative comprehensive reviews or short overviews of topics of current interest; (c) brief but urgent communications on new significant research; and (d) commentaries intended to foster the exchange of innovative or provocative ideas, and to encourage dialogue, amongst researchers working in different cluster disciplines.